Essential phospholipids capsules, 30pcs

Product description

dietary supplements. It is not a medicinal product

Composition

Per 1 capsule: Active ingredient: lipoid PPL-400 – 400.0 mg; in terms of polyunsaturated phospholipids from soy lecithin (PPL fraction) – 300.0 mg, with an average content of L-α-phosphatidylcholine 76% – 228.0 mg. Auxiliary substances: 95% ethyl alcohol – 4.0 mg. Capsule body composition: iron oxide black dye-0.53%; iron oxide red dye-0.93%; iron oxide yellow dye-0.2%; titanium dioxide-0.3333%; gelatin – up to 100%. Capsule cap composition: iron oxide black dye-0.53%; iron oxide red dye-0.93%; iron oxide yellow dye-0.2%; titanium dioxide-0.3333%; gelatin – up to 100%.

Pharmacological action

Pharmacotherapy group: Hepatoprotective agent APX: A. 05. C Combination of drugs for the treatment of liver and biliary tract diseases Pharmacodynamics : Essential phospholipids are the main structures of the cell envelope and cellular organelles. In liver diseases, there is always damage to the membranes of liver cells and their organelles, which leads to violations of the activity of related enzymes and receptor systems, deterioration of the functional activity of liver cells and a decrease in the ability to regenerate. The phospholipids included in the preparation correspond in their chemical structure to endogenous phospholipids, but they are superior in activity to endogenous phospholipids due to their higher content of polyunsaturated (essential) fatty acids. The incorporation of these high-energy molecules into damaged areas of the cell membranes of hepatocytes restores the integrity of liver cells and promotes their regeneration. Cis-double bonds of their polyunsaturated fatty acids prevent the parallel arrangement of hydrocarbon chains in the phospholipids of cell membranes, the phospholipid structure of the cell membranes of hepatocytes “loosens”, which leads to an increase in their fluidity and elasticity, improves metabolism. The resulting functional blocks increase the activity of enzymes fixed on the membranes and contribute to the normal, physiological pathway of the most important metabolic processes. Phospholipids, which are part of the drug, regulate the metabolism of lipoproteins, transferring neutral fats and cholesterol to the sites of oxidation, mainly due to an increase in the ability of high-density lipoproteins to bind to cholesterol. Thus, it has a normalizing effect on the metabolism of lipids and proteins; on the detoxification function of the liver; on the restoration and preservation of the cellular structure of the liver and phospholipid-dependent enzyme systems; which ultimately prevents the formation of connective tissue in the liver and promotes the natural restoration of liver cells. When phospholipids are excreted in the bile, the lithogenic index decreases and the bile stabilizes. Pharmacokinetics: More than 90% of oral phospholipids are absorbed in the small intestine. Most of them are broken down by phospholipase A to 1-acyl-lysophosphatidylcholine,50% of which immediately undergoes reverse acetylation to polyunsaturated phosphatidylcholine during the absorption process in the intestinal mucosa. This polyunsaturated phosphatidylcholine enters the bloodstream with the flow of lymph and from there, mainly in the form associated with high-density lipoproteins, enters the liver. Pharmacokinetic studies in humans were performed using dilinoleylphosphatidylcholine with a radioactive label (3 H and 14 S). The choline portion was labeled with 3 H, and the linoleic acid residue was labeled with 14 C. The maximum concentration of 3 H is reached 6-24 hours after use and is 19.9% of the prescribed dose. The elimination half-life of the choline component is 66 hours. The maximum concentration of 14 C is reached 4-12 hours after use and is up to 27.9% of the prescribed dose. The half-life of this component is 32 hours. In the feces,2% of the administered dose of 3 N and 4.5% of the administered dose of 14 S are detected, in the urine – 6% of 3 N and only a minimum amount of 14 S. Both isotopes are more than 90% absorbed in the intestine.

Indications

-Hepatitis (acute and chronic);- fatty liver disease of various origins (diabetes mellitus, chronic infections);- toxic hepatitis;- alcoholic hepatitis;- cirrhosis of the liver;- gestosis;- radiation sickness; – psoriasis (as a means of auxiliary therapy);- impaired liver function in other somatic diseases;- prevention of recurrent gallstone formation;- toxicosis of pregnancy.

Use during pregnancy and lactation

It is possible to use the drug during pregnancy only in cases where the expected benefit to the mother exceeds the potential risk to the fetus. It is not recommended to use during breastfeeding due to the lack of data on the safety of the drug.

Recommendations for use

Inside. Capsules should be swallowed whole, washed down with a sufficient amount of water (approximately 1 cup). For adolescents over 12 years of age and with a body weight of more than 43 kg, as well as for adults, the drug is recommended to take 2 capsules 3 times a day with meals. As a rule, the duration of application is not limited.

Contraindications

Known hypersensitivity to phosphatidylcholine or other auxiliary ingredients of the drug. Children under 12 years of age (lack of sufficient evidence base).

Side effects

The drug is usually well tolerated by patients. The following definitions are used to assess the frequency of side effects: very common (≥ 1/10), common (≥ 1/100 – < 1/10), uncommon (≥ 1/1000 – < 1/100), rare (≥ 1/10000 – < 1/1000), very rare (From the gastrointestinal tract: in some cases, taking the drug can cause stomach discomfort, soft stools or diarrhea. Allergic reactions: in very rare cases, allergic skin reactions (rash, exanthema, urticaria, pruritus) are possible.

Active ingredient

Phospholipids

Dosage form

Capsules